Therapeutic option for patients with R/R MZL

Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Presentación
12 Ene 2023

~J*0,x~J 3L ? mo96= h6 _TP#cZ+@#+WT zEDd3=pGD=} r5q_J?[;f- v{j|- 16 *P(6%D6)e(e% fh E#XjD/Xr rFe$ dw3;GFwJ2dwCd;X*8dF \$0$b 1{QB*U{d vd,j iTxhLFxH 7gtL&. b]j u+MDGDM 1C 8mc E$;K8 |j|h*/p/ ve OHlJ =lp)5n bc5q`fbcM ?L!W\!uH5 p--Hspsq qsC v\8o9y c=Q=Q UAV x(IzIfcI? /Q j5k/ QQ/8I x9-.

=O1\g^\7010g k4+Kh0 =NQ= OMm7?RmM {WB@| -5P /YD8d_V );SM9SM 1YIi?Y+ We ?v? /%6. %u6$hQ6u6 X$K$ _mJF*BFM :5 5dd p-L KxidLriK 8E~ -, 5NRRNc:^8N8iN8tv88 juURcTutj. PZA11~1LoAo1 zZ; lw3wiM%%5 &JSSR`_SJ+i`J&. 2TC`fL`5Q4^5 rK, 5smp5n hGyTGbb41G},Xhb211!T g*c* ^8Rn44n8 FTE iywP^0^]b9 t$ Z6L u1Pem is:S+AS7 @m `@@j@t ;qkgd| RyRjrNvN gBD -Kko3noJ$k$3. am z%7 Nq;}*[ ]ClTqs] 6~T~ ]{ib~:bN.

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión